JPS5538325A
(en)
|
1978-09-11 |
1980-03-17 |
Sankyo Co Ltd |
4-anilinoquinazoline derivative and its preparation
|
US4335127A
(en)
|
1979-01-08 |
1982-06-15 |
Janssen Pharmaceutica, N.V. |
Piperidinylalkyl quinazoline compounds, composition and method of use
|
GB2160201B
(en)
|
1984-06-14 |
1988-05-11 |
Wyeth John & Brother Ltd |
Quinazoline and cinnoline derivatives
|
KR910006138B1
(ko)
|
1986-09-30 |
1991-08-16 |
에자이 가부시끼가이샤 |
환상아민 유도체
|
IL89029A
(en)
|
1988-01-29 |
1993-01-31 |
Lilly Co Eli |
Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
|
US4921863A
(en)
|
1988-02-17 |
1990-05-01 |
Eisai Co., Ltd. |
Cyclic amine derivatives
|
CA1340821C
(en)
|
1988-10-06 |
1999-11-16 |
Nobuyuki Fukazawa |
Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
|
WO1992020642A1
(en)
|
1991-05-10 |
1992-11-26 |
Rhone-Poulenc Rorer International (Holdings) Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
|
US5710158A
(en)
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
US5721237A
(en)
|
1991-05-10 |
1998-02-24 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
PT100905A
(pt)
|
1991-09-30 |
1994-02-28 |
Eisai Co Ltd |
Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
|
US5187168A
(en)
|
1991-10-24 |
1993-02-16 |
American Home Products Corporation |
Substituted quinazolines as angiotensin II antagonists
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO1993017682A1
(en)
|
1992-03-04 |
1993-09-16 |
Abbott Laboratories |
Angiotensin ii receptor antagonists
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
JPH083144A
(ja)
|
1994-06-21 |
1996-01-09 |
Chugai Pharmaceut Co Ltd |
キナゾリン及びキノリン誘導体
|
GB9510757D0
(en)
|
1994-09-19 |
1995-07-19 |
Wellcome Found |
Therapeuticaly active compounds
|
TW321649B
(xx)
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB2295387A
(en)
|
1994-11-23 |
1996-05-29 |
Glaxo Inc |
Quinazoline antagonists of alpha 1c adrenergic receptors
|
GB9424233D0
(en)
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
EP1110953B1
(en)
|
1995-03-30 |
2009-10-28 |
Pfizer Products Inc. |
Quinazoline derivatives
|
GB9508535D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9508537D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
EP0824525B1
(en)
|
1995-04-27 |
2001-06-13 |
AstraZeneca AB |
Quinazoline derivatives
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US6046206A
(en)
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
|
GB9514265D0
(en)
|
1995-07-13 |
1995-09-13 |
Wellcome Found |
Hetrocyclic compounds
|
EP0850055B1
(en)
|
1995-09-11 |
2005-06-29 |
Osteoarthritis Sciences, Inc. |
Protein tyrosine kinase inhibitors for treating osteoarthritis
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
CA2216169C
(en)
|
1996-01-31 |
2007-01-23 |
Gist-Brocades B.V. |
Use of compositions comprising stabilized biologically effective compounds
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
KR19990082463A
(ko)
|
1996-02-13 |
1999-11-25 |
돈 리사 로얄 |
혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
EP0892789B2
(en)
|
1996-04-12 |
2009-11-18 |
Warner-Lambert Company LLC |
Irreversible inhibitors of tyrosine kinases
|
AR007857A1
(es)
|
1996-07-13 |
1999-11-24 |
Glaxo Group Ltd |
Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
|
US6004967A
(en)
|
1996-09-13 |
1999-12-21 |
Sugen, Inc. |
Psoriasis treatment with quinazoline compounds
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
WO1998038984A2
(en)
|
1997-03-05 |
1998-09-11 |
Sugen, Inc. |
Formulations for hydrophobic pharmaceutical agents
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
CN1195521C
(zh)
|
1997-05-06 |
2005-04-06 |
惠氏控股公司 |
喹唑啉化合物在治疗多囊肾病中的应用
|
US5929080A
(en)
|
1997-05-06 |
1999-07-27 |
American Cyanamid Company |
Method of treating polycystic kidney disease
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
PL340800A1
(en)
|
1997-11-06 |
2001-02-26 |
American Cyanamid Co |
Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps
|
JP4245682B2
(ja)
|
1997-12-25 |
2009-03-25 |
協和発酵キリン株式会社 |
キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
HUP0102793A3
(en)
|
1998-05-28 |
2002-07-29 |
Parker Hughes Inst St Paul |
Quinazolines for treating brain tumor and medicaments containing them
|
WO2000000202A1
(en)
|
1998-06-30 |
2000-01-06 |
Parker Hughes Institute |
Method for inhibiting c-jun expression using jak-3 inhibitors
|
US6384223B1
(en)
|
1998-07-30 |
2002-05-07 |
American Home Products Corporation |
Substituted quinazoline derivatives
|
WO2000006555A1
(en)
|
1998-07-30 |
2000-02-10 |
American Home Products Corporation |
Substituted quinazoline derivatives
|
WO2000009481A1
(fr)
|
1998-08-11 |
2000-02-24 |
Takeda Chemical Industries, Ltd. |
Composes d'amide cyclique, procedes de production correspondants, intermediaires correspondants et herbicides
|
WO2000010981A1
(en)
|
1998-08-21 |
2000-03-02 |
Parker Hughes Institute |
Quinazoline derivatives
|
SI2253620T1
(sl)
|
1998-09-29 |
2014-06-30 |
Wyeth Holdings Llc |
Substituirani 3-cianokinolini kot inhibitorji protein tirozin-kinaz
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
NZ510210A
(en)
|
1998-10-01 |
2003-06-30 |
Astrazeneca Ab |
4-phenylamino substituted quinazoline or quinoline derivatives useful for treating cytokine mediated diseases or conditions
|
TW575567B
(en)
|
1998-10-23 |
2004-02-11 |
Akzo Nobel Nv |
Serine protease inhibitor
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
KR20080015482A
(ko)
|
1999-02-10 |
2008-02-19 |
아스트라제네카 아베 |
혈관형성 억제제로서의 퀴나졸린 유도체
|
DE19908567A1
(de)
|
1999-02-27 |
2000-08-31 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
BR0008524A
(pt)
|
1999-02-27 |
2001-12-18 |
Boehringer Ingelheim Pharma |
Heterociclos bicìclicos, composiçõesfarmacêuticas que contêm esses compostos, seuuso e processos para a sua prerapação
|
US6080747A
(en)
|
1999-03-05 |
2000-06-27 |
Hughes Institute |
JAK-3 inhibitors for treating allergic disorders
|
DE19911509A1
(de)
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
UA73993C2
(uk)
*
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
DE10040527A1
(de)
|
2000-08-18 |
2002-02-28 |
Boehringer Ingelheim Pharma |
Chinazoline und Verfahren zu ihrer Herstellung
|
US20020082270A1
(en)
|
2000-08-26 |
2002-06-27 |
Frank Himmelsbach |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
US6617329B2
(en)
|
2000-08-26 |
2003-09-09 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines and their use as medicaments
|
NZ516873A
(en)
|
2001-02-12 |
2003-11-28 |
Warner Lambert Co |
Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
|
JP4285996B2
(ja)
|
2001-02-21 |
2009-06-24 |
田辺三菱製薬株式会社 |
キナゾリン誘導体
|
US6562319B2
(en)
|
2001-03-12 |
2003-05-13 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
|
JPWO2002094790A1
(ja)
|
2001-05-23 |
2004-09-09 |
三菱ウェルファーマ株式会社 |
縮合ヘテロ環化合物およびその医薬用途
|
GB0126433D0
(en)
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
BR0213842A
(pt)
*
|
2001-11-03 |
2004-08-31 |
Astrazeneca Ab |
Derivado de quinazolina ou um sal deste farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, e, uso do derivado de quinazolina ou de um sal deste farmaceuticamente aceitável
|
TWI324597B
(en)
|
2002-03-28 |
2010-05-11 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0309009D0
(en)
|
2003-04-22 |
2003-05-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
BRPI0413066A
(pt)
|
2003-07-29 |
2006-10-17 |
Astrazeneca Ab |
derivado de quinazolina, ou um sal farmaceuticamente aceitável, ou um éster farmaceuticamente aceitável do mesmo, da fórmula i, uso e processo para a preparação do mesmo, composto, composição farmacêutica, e, métodos para a produção de um efeito antiproliferativo em um animal de sangue quente, para a prevenção ou tratamento de um tumor, para prover um efeito inibitório de tirosina quinase de egfr seletivo, e para tratar um cáncer em um animal de sangue quente
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
CA2538884C
(en)
|
2003-09-16 |
2010-09-21 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
GB0321648D0
(en)
*
|
2003-09-16 |
2003-10-15 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO2005026151A1
(en)
*
|
2003-09-16 |
2005-03-24 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
AU2004272346A1
(en)
|
2003-09-16 |
2005-03-24 |
Astrazeneca Ab |
Quinazoline derivatives
|
EP1670782B1
(en)
|
2003-09-19 |
2007-02-14 |
AstraZeneca AB |
Quinazoline derivatives
|
BRPI0414735A
(pt)
|
2003-09-25 |
2006-11-21 |
Astrazeneca Ab |
derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
CN1914182B
(zh)
|
2004-02-03 |
2011-09-07 |
阿斯利康(瑞典)有限公司 |
喹唑啉衍生物
|
KR20070038500A
(ko)
|
2004-06-04 |
2007-04-10 |
아스트라제네카 아베 |
erbB 수용체 타이로신 키나제로서의 퀴나졸린 유도체
|